Please ensure Javascript is enabled for purposes of website accessibility

2 Best Cannabis Stocks to Buy in August

By George Budwell - Aug 1, 2019 at 10:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Auxly Cannabis Group and Charlotte's Web Holdings are poised for serious growth.

The vast majority of cannabis stocks flat out wilted under the summer heat in 2019. Top dogs like Aphria, Aurora Cannabis, and Canopy Growth (CGC 0.26%) all saw their market caps take a whopping 20% haircut in just the past 30 days.

The industry's recent move lower reflected a variety of negative headwinds, such as abrupt changes in management at bellwether companies like Canopy Growth and MedMen Enterprises, a fair number of scandals, looming oversupply in the Canadian adult-use market, as well as a host of underwhelming earnings reports. 

A crop of marijuana growing outdoors.

Image Source: Getty Images.

The legal cannabis space, though, arguably needed this reality check. Stock valuations have gotten way out of hand this year, especially in light of the fact that the biggest potential markets have yet to fully legalize either medical or recreational marijuana. 

Given the chaotic nature of the nascent cannabis market, it's important for investors to carefully consider which companies have the right mix of ingredients to first weather this ongoing maelstrom, and then become profitable entities over the long run.

Auxly Cannabis Group (CBWTF -6.60%) and Charlotte's Web Holdings (CWBHF -18.65%) stand out as two that might have what it takes -- making them strong potential additions to any cannabis-oriented portfolio this month. Here's a brief overview of these promising cannabis stocks.    

A hidden gem

Auxly might be a penny stock, but that doesn't mean this small-cap cannabis company isn't worth your attention right now. It's gearing up to become a major player in the derivative cannabis product space, once this segment officially opens in Canada this December.

Branded derivative products such as edibles, extracts, and topicals have both higher profit margins than dried flowers and inherently stronger economic moats. While growing your own weed isn't exactly rocket science, it is considerably more challenging for the average consumer -- or even black market retailers -- to knock out high-quality extracts. So Auxly's strategy of prioritizing branded derivatives has a solid rationale behind it -- even though this slow-motion plan of attack has forced the company to repeatedly dilute shareholders to stay afloat.

Now, Auxly's moment in the sun is finally close at hand. Based on Canada's regulatory calendar, derivative products will start showing up on dispensary shelves in December, so Auxly's top line should begin growing by leaps and bounds next year. Wall Street, in fact, forecasts its sales will increase by an astronomical 3,169% in 2020. 

The real reason to buy this stock now, however, is Auxly's newly minted partnership with U.K. tobacco giant Imperial Brands, which bought a 19.9% stake in the cannabis specialist and granted it access to its world-class vape platform. Although this deal is nowhere near the size of either Canopy's tie-up with Constellation Brands or Cronos Group's megadeal with Altria, it should provide Auxly the capital to stay afloat while the high-value derivative cannabis market comes online. So while this growth story won't materialize overnight, Auxly does appear to be on the right track.  

A leader in the rapidly emerging hemp cannabidiol (CBD) space

The market for hemp-based CBD products is forecast to hit $7.5 billion by 2024 -- and that's one of the lower-end estimates. Leading cannabis research firms BDS Analytics and Arcview Market Research estimate that the CBD market could surpass $20 billion in sales by then. That bodes well for leaders in the space such as Charlotte's Web Holdings. 

Charlotte's Web is expected to win a roughly 20% share of the hemp-based CBD product market next year. So if the company can simply hold onto its piece of the pie during the coming period of hyper-growth, its annual sales should easily exceed $1.6 billion by the end of 2024. That works out to a stellar compound annual growth rate of 37.8%, putting Charlotte's Web in the running to be one of the fastest-growing companies in the world. 

Can Charlotte's Web grow in lockstep with the hemp-based CBD market? The answer appears to be a resounding yes. With a top-notch production capacity and marquee distribution deals in place with heavyweights like CVS Health and Kroger, this top hemp company is poised for explosive growth in the years to come. As such, growth-oriented investors may want to strongly consider buying this small-cap cannabis stock soon. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Auxly Cannabis Group, Constellation Brands, CVS Health, and Imperial Brands. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Auxly Cannabis Group Inc. Stock Quote
Auxly Cannabis Group Inc.
$0.05 (-6.60%) $0.00
Charlotte's Web Holdings, Inc. Stock Quote
Charlotte's Web Holdings, Inc.
$0.55 (-18.65%) $0.13
Canopy Growth Stock Quote
Canopy Growth
$3.82 (0.26%) $0.01
Cronos Group Stock Quote
Cronos Group
$3.82 (-4.74%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.